The platform has special utility in supporting the creation of drugs for hard-to-treat diseases such as Alzheimer's, which affect large numbers of people. To this end, the company has partnered with leading pharmaceutical companies such as Merck & Co and Amgen to build ML and AI platforms for their drug discovery needs.

Interestingly, BigHat grew its company by 30% in 2022, despite competitors having to downsize, which is a a definitive green flag for its success in the space. It has also won big when it comes to large contractors who see the smoothness and scalability of the platforms it builds, suggesting it will secure more lucrative deals moving forward.